| P50 | author | Matthias A. Karajannis | Q47163156 |
| P2093 | author name string | Amar Gajjar | |
| | Daniel C Bowers | |
| | Hendrik Witt | |
| | Sarah Leary | |
| | Nicholas G Gottardo | |
| P2860 | cites work | Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. | Q45944762 |
| | Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. | Q45959776 |
| | A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). | Q46088442 |
| | Outcome analysis of childhood low-grade astrocytomas | Q46350472 |
| | Treatment of early childhood medulloblastoma by postoperative chemotherapy alone | Q46367739 |
| | Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors | Q46669775 |
| | Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 |
| | Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. | Q47992753 |
| | Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood | Q48290742 |
| | Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Q48329991 |
| | Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue. | Q48410114 |
| | IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value? | Q48606060 |
| | Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital | Q48651367 |
| | Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy | Q48693115 |
| | BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. | Q54587637 |
| | Radiotherapy in pediatric pilocytic astrocytomas. A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). | Q55461552 |
| | Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. | Q55463341 |
| | Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. | Q55469539 |
| | Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. | Q55476479 |
| | Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial | Q71848701 |
| | Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy | Q73798189 |
| | Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma | Q34132926 |
| | Bevacizumab in recurrent high-grade pediatric gliomas | Q34133084 |
| | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 |
| | Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. | Q34193749 |
| | Epigenomic alterations define lethal CIMP-positive ependymomas of infancy | Q34240198 |
| | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma | Q34362028 |
| | Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition | Q34426872 |
| | Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group | Q34722440 |
| | Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group | Q34722864 |
| | Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma | Q34810691 |
| | Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts | Q35053098 |
| | Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma | Q35135650 |
| | Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. | Q35146078 |
| | An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. | Q35212577 |
| | Challenging issues in pediatric oncology | Q35602419 |
| | Novel mutations target distinct subgroups of medulloblastoma. | Q36143877 |
| | Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group | Q36145437 |
| | PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma | Q36157714 |
| | BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. | Q36239628 |
| | Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology | Q36261364 |
| | Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database | Q36311369 |
| | Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups | Q36461766 |
| | Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables | Q36476670 |
| | Phase II trial of conformal radiation therapy for pediatric low-grade glioma | Q36476957 |
| | Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study | Q36485991 |
| | BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas | Q36532504 |
| | Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma | Q36659706 |
| | Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis | Q36737213 |
| | Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas | Q36762579 |
| | Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma | Q36929844 |
| | High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031) | Q37066730 |
| | A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. | Q37284226 |
| | Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours | Q37330655 |
| | Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study | Q37375947 |
| | Medulloblastomics: the end of the beginning | Q37469904 |
| | Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study | Q37492128 |
| | Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies | Q37586811 |
| | Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012. | Q37595251 |
| | Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial | Q37612212 |
| | Cytogenetic prognostication within medulloblastoma subgroups | Q37627692 |
| | Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years | Q37665521 |
| | Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma | Q37705192 |
| | Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge | Q37729676 |
| | Molecular diagnostics of CNS embryonal tumors | Q37794829 |
| | Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. | Q37949049 |
| | Development and classes of epigenetic drugs for cancer | Q38228661 |
| | Medulloblastoma-translating discoveries from the bench to the bedside | Q38263111 |
| | Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study | Q38423271 |
| | A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes | Q39047678 |
| | BET bromodomain inhibition of MYC-amplified medulloblastoma. | Q39050679 |
| | Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma | Q39788891 |
| | Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis | Q39828521 |
| | Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers | Q41264935 |
| | Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors | Q41817349 |
| | Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma | Q41888346 |
| | Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 | Q42031842 |
| | LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR) | Q42085653 |
| | Update on molecular and genetic alterations in adult medulloblastoma | Q42647486 |
| | Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. | Q42739353 |
| | Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma | Q42812964 |
| | Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol | Q43231168 |
| | Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database | Q43944813 |
| | Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study | Q44405254 |
| | Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma | Q44739121 |
| | Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial | Q45120061 |
| | Relapse patterns in pediatric embryonal central nervous system tumors | Q45186104 |
| | Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma | Q45345277 |
| | Molecular subgroups of medulloblastoma: the current consensus | Q24615271 |
| | Dissecting the genomic complexity underlying medulloblastoma | Q24621907 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists | Q24632161 |
| | The 2007 WHO classification of tumours of the central nervous system | Q24685772 |
| | Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition | Q27852966 |
| | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 |
| | Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy | Q28237056 |
| | Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma | Q28237518 |
| | Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations | Q28237528 |
| | Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma | Q28237604 |
| | Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood | Q28270587 |
| | Subgroup-specific structural variation across 1,000 medulloblastoma genomes | Q28271811 |
| | Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group | Q28277811 |
| | beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee | Q28279527 |
| | Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors | Q28294240 |
| | Rapamycin causes regression of astrocytomas in tuberous sclerosis complex | Q28295149 |
| | Subtypes of medulloblastoma have distinct developmental origins | Q28300616 |
| | Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor | Q29303793 |
| | Cancer epigenetics: from mechanism to therapy | Q29614799 |
| | Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 |
| | Prediction of central nervous system embryonal tumour outcome based on gene expression | Q29618619 |
| | Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations | Q30040534 |
| | A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 |
| | A prognostic gene expression signature in infratentorial ependymoma | Q33581494 |
| | C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma | Q33730977 |
| | The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma | Q33751426 |
| | Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene | Q33772206 |
| | Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity | Q33917715 |
| | Cross-species genomics matches driver mutations and cell compartments to model ependymoma | Q34031780 |
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain tumor | Q233309 |
| P304 | page(s) | 2986-2998 | |
| P577 | publication date | 2015-08-24 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape | |
| P478 | volume | 33 | |